SCRC

Section 1

A Message Regarding Prop 14
CIRM Approves New Clinical Trials
Q&A with Dr. Anderson

About Us

Today’s UC Irvine Stem Cell Research Center is a dynamic center encompassing a diverse array of interdisciplinary investigators that span the schools of Medicine, Biological Sciences, Pharmaceutical Sciences, Engineering, Arts and Law. Our state-of-the-art, LEED Platinum certified research and clinical building houses 23 of our 50 center faculty members.

Center faculty have obtained more than $170 million dollars in grant and foundation funds
. Our research programs include an National Institutes of Health (NIH)-sponsored T32 training grant, state of the art shared equipment, research services programs and a seminar series.

What can we do for you?

Researchers

Research areas, available resources and clinical trials

Patients

Learn about our clinical research and trials

Donors

Learn how you can support stem cell research at UCI

Community

See the latest news, videos and upcoming events

Events

Community lectures, special events and opportunities to engage. Find details for future events here.

Hematopoietic Stem Cells: From Embryonic Origins to Therapeutic Use

  • 2020-2021 Stem Cell Seminar Series
  • Matt Inlay, PhD
  • Friday, Feb. 05, 2021
    11:00 AM - 12:00 PM PDT
  • No registration required

Inflammatory Modulators in Adult Stem Cell Therapy

  • 2020-2021 Stem Cell Seminar Series
  • Laura Suggs, PhD
  • Friday, Mar. 05, 2021
    11:00 AM - 12:00 PM PDT
  • No registration required

News

Married Scientists Fight Against Breast Cancer

Irvine, Calif. - October 20, 2020 – Both are researchers at UC Irvine. Though they focus on different areas of breast cancer research, their goal is the same.

Advancing Breakthough Science

Irvine, Calif. - October 14, 2020 – In this Q&A, center director Aileen Anderson discusses some key accomplishments and describes the importance of stem cell research.

Biomedical's Stem Cell Therapeutic in Vision Loss

Irvine, Calif. - October 13, 2020 – AIVITA Biomedical, Inc. developing vaccines for the treatment of cancer and COVID-19, announced peer-reviewed manuscript.